Maze Therapeutics Reports Q3 2026 Financial Results
The clinical-stage biotech reported a third-quarter net loss of $48.0 million while advancing its Phase 2 HORIZON trial of MZE829.
Updated on Nov. 9, 2026 in Corporate Finance

Maze Therapeutics, headquartered in South San Francisco, reported third quarter 2026 financial results, including a net loss of $48.0 million and cash, equivalents and marketable securities of $477.0 million as of September 30, 2026. The company also reported that it completed enrollment in the Phase 2 HORIZON trial of MZE829 with more than 50 patients.
Why it matters
The results show a clinical-stage biotech funding its pipeline through a rising research spend, with its cash position supported in part by a $20.0 million license milestone from Shionogi & Co., Ltd. The company expects its current resources to fund operations into 2029.
Cash, equivalents and marketable securities reached $477.0 million at September 30, 2026, up from $360.0 million at year-end 2025. Third-quarter net loss was $48.0 million, or $0.79 per share, with final HORIZON data and pivotal-trial timing still pending.
The players
Maze Therapeutics
A clinical-stage biotechnology company headquartered in South San Francisco that is developing MZE829 and MZE782 for kidney disease.
Shionogi & Co., Ltd.
A Japanese pharmaceutical company that holds an exclusive license agreement with Maze Therapeutics and paid a milestone in 2026.
The details
Research and development expenses increased to $40.2 million in the quarter, driven by progression of the MZE829 and MZE782 programs and higher personnel costs, including non-cash stock-based compensation. General and administrative expenses rose to $11.3 million on higher personnel and professional services costs.
Timeline
Dec. 31, 2025: Prior year-end cash balance of $360.0 million is recorded.
Q1 2026: A Shionogi milestone triggers $20.0 million in license revenue.
August 2026: Paula Johnson and Sophie Kornowski are appointed to the Board of Directors.
Oct. 21-25, 2026: HORIZON data are presented at ASN Kidney Week in Denver, Colorado.
Sept. 30, 2026: Quarter ends with $477.0 million in cash and securities.
Market Dynamics
Maze's reliance on partner milestone payments alongside equity-funded spending reflects a common funding pattern among clinical-stage biotechs. Its expected runway into 2029 gives it room to advance MZE829 toward a pivotal trial in the first half of 2027, subject to regulatory feedback.
For investors, the company's cash runway into 2029 reduces near-term financing pressure while it works toward the final HORIZON readout. The timing of that data and the pivotal trial start will shape how the stock is valued in 2027.
The takeaway
Clinical-stage biotechs often extend their runway through partner milestones and equity raises, so investors should track the next data readout and trial start dates. Maze's 2029 runway hinges on those upcoming catalysts.
What happens next
Maze expects to announce final HORIZON data in early 2027 and plans to initiate a pivotal trial of MZE829 in the first half of 2027, subject to regulatory feedback.
Further reading
For more on company financing and balance sheets, see Corporate Finance coverage for South San Francisco.
Source note: This article includes information reported by The Manila times.










